VT-104
oral pan-TEAD auto-palmitoylation inhibitor tumor regression at 3 mg/kg QD from 160k compound cell-based HTS Mol. Cancer. Ther., Apr. 13, 2021 Vivace Therapeutics, San Mateo, CA
Molecules of the Month - April 2021
Molecules of the Month
- RM-018
- GDC-0334
- BAY 1101042 (runcaciguat)
- AG-270
- NJH-2-057
- basmisanil
- STM-2457
- compound 28
- VT-104
- CB-5083
- compound 20p
- SHR168442
- GNE-9815
- ABD957